Gemcitabine plus cisplatin (GC) : a salvage regimen for advanced breast cancer patients who have failed anthracycline and/or taxane therapy
Chitapanarux, I.; Lorvidhaya, V.; Kamnerdsupaphon, P.; Tharavichitkul, E.; Trakultivakorn, H.; Somwangprasert, A.; Sumitsawan, S.; Srisukho, S.; Watcharachan, K.; Sukthomya, V.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(6): 761-766
2006
ISSN/ISBN: 0385-0684 PMID: 16770093 Document Number: 596991
In clinical studies of both heavily and minimally pretreated patients with advanced breast cancer, the combination of Gemcitabine plus cisplatin (GC), given in a variety of schedules and doses, has demonstrated moderate safety and efficacy in both heavily and minimally pretreated advanced breast cancer with response rate from 29-63% (median 46%). We evaluated the activity and toxicity of another GC regimen (gemcitabine 1,000 mg/m(2) days 1, 8 plus cisplatin 75 mg/m(2) day 1 every 3 weeks) in 30 breast cancer patients who failed chemotherapy with anthracycline and/or taxanes as adjuvant or neoadjuvant, or primary therapy. We obtained overall response in 15 of 29 evaluable patients (52%), with responses occurring in all subgroups of disease (unresectable locally advanced, locoregional recurrence, and distant metastasis). Toxicity was primarily hematologic, with grade 3/4 neutropenia and thrombocytopenia in 37% and 17% of patients, respectively. The only grade 3/4 non-hematologic toxicity was grade 3 nausea/vomiting in 12% of patients. Our data suggest that gemcitabine plus cisplatin appears to be effective and has an acceptable toxicity profile in anthracycline and/or taxane pretreated patients with advanced breast cancer.